# IN10018 in Combination With Dalpiciclib for Progressive Meningiomas

> **NCT07652762** · PHASE1 · RECRUITING · sponsor: **Capital Medical University** · enrollment: 24 (estimated)

## Conditions studied

- Meningioma
- CDK4/6 Inhibitor

## Interventions

- **DRUG:** Ifebemtinib
- **DRUG:** Dalpiciclib

## Key facts

- **NCT ID:** NCT07652762
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-08
- **Final completion:** 2029-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652762, "IN10018 in Combination With Dalpiciclib for Progressive Meningiomas". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*